Tyra biosciences announces oral presentations on tyra-300 for achondroplasia at the asbmr and ashg 2023 annual meetings

Carlsbad, calif. , sept. 21, 2023 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today announced that tyra will deliver oral presentations on tyra-300 for achondroplasia at the american society for bone and mineral research (asbmr) and the american society of human genetics (ashg) 2023 annual meetings.
TYRA Ratings Summary
TYRA Quant Ranking